Recent Publications or news items

[drc007]

We ignore the disaster in the antibiotics market at our peril Financial Times article on economics of Antibiotic Research.

[drc007]

Now free access at Wellcome

https://wellcome.ac.uk/news/we-ignore-disaster-antibiotics-market-our-peril

[drc007]

In the review repository

March 29 2019 Needham Review.pdf Antibiotic R&D Update 20. Link.

Tackling antimicrobial Resistance 2019-2024, the UK's five-year national action plan.(Published 24 January 2019) Link

[mattodd]

Great idea to start this. I'd hope we might aggregate these into the wiki area about the literature around AMR etc, but this acts as a useful place to jot things down as they arise.

[drc007]

NO TIME TO WAIT:
SECURING THE FUTURE FROM DRUG-RESISTANT INFECTIONS
REPORT TO THE SECRETARY-GENERAL OF THE UNITED NATIONS
APRIL 2019 Link

[drc007]

Five-Year Analysis Shows Continued Deficiencies in Antibiotic Development
Visualization tool lets users track the pipeline from 2014 to 2018
https://www.pewtrusts.org/en/research-and-analysis/data-visualizations/2019/five-year-analysis-shows-continued-deficiencies-in-antibiotic-development

[drc007]

CO-ADD is a non-for-profit initiative led by academics at The University of Queensland. Our goal is to screen compound for antimicrobial activity for academic research groups and generate a public knowledge database for the development of novel agents for the treatment of microbial infections. The knowledge base contains chemical structures and antimicrobial activity data from CO-ADD’s screening, made publicly available by the academic research groups, with more data to be released over time. https://db.co-add.org/screening-data/

[drc007]

Epidemic of carbapenem-resistant Klebsiella pneumoniae in Europe is driven by nosocomial spread https://www.bbc.co.uk/news/health-49132425
https://www.nature.com/articles/s41564-019-0492-8

[drc007]

Bacteria which are resistant to antibiotics has been found within the tonnes of sewage dumped into the River Thames.
https://www.bbc.co.uk/news/av/uk-england-london-49435120/antibiotic-resistant-bacteria-found-in-river-thames

[drc007]

Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis

From EARS-Net data collected between Jan 1, 2015, and Dec 31, 2015, we estimated 671689 (95% uncertainty interval [UI] 583148–763966) infections with antibiotic-resistant bacteria, of which 63·5% (426277 of 671689) were associated with health care. These infections accounted for an estimated 33110 (28480–38430) attributable deaths and 874541 (768837–989068) DALYs. The burden for the EU and EEA was highest in infants (aged <1 year) and people aged 65 years or older, had increased since 2007, and was highest in Italy and Greece

Link

[drc007]

Call for Papers: Antibiotics Special Issue DOI.

To highlight new advances in antibiotic development, ACS Infectious Diseases and ACS Pharmacology & Translational Science will publish a joint Special Issue on the topic in mid-2020. Succinctly entitled “Antibiotics”, the Special Issue welcomes research from academics, not-for-profits, and industry on research related to the discovery and development of new antibiotics and antibiotic potentiators, submitted as Articles, Letters, Reviews, Viewpoints, and Perspectives. Ideally, this issue will provide a sampling of the different approaches to new antibiotic development, including advances based on the more traditional pathways of improving existing classes of antibiotics, rediscovering “lost” antibiotics from decades ago, and potentiating existing antibiotics to rescue them from obsolescence. We strongly encourage the submission of research featuring promising new chemotypes acting on novel targets: the Holy Grail of antibiotic discovery. While new antimicrobials based on novel modalities have proven to be exceedingly difficult to advance all the way to drug approval, substantial advances have been made with programs such as LpxC inhibitors.

[drc007]

Drug-resistant infections: the science is on track, but the economics need fixing.
https://wellcome.ac.uk/what-we-do/our-work/drug-resistant-infections/drug-resistant-infections-science-economics?utm_source=twitter&utm_medium=ad-wellcome&utm_campaign=dri_market_incentives&utm_content=pharma-image-infographic

[drc007]

How to communicate about antimicrobial resistance effectively https://wellcome.ac.uk/reports/reframing-antimicrobial-resistance-antibiotic-resistance

[mattodd]

Super interesting NHS trial that is compatible with open source. Must add to e.g. wiki sources summarising funding mechanisms/ideas.

New antibiotics: NHS will test “pay for usefulness” model to stimulate research
BMJ 2019; 366 doi: https://doi.org/10.1136/bmj.l4610 (Published 09 July 2019) Cite this as: BMJ 2019;366:l4610
https://www.bmj.com/content/366/bmj.l4610
"The NHS will pay drug companies up front for access to new drugs depending on their usefulness, in an effort to encourage them to invest the £1bn (€1.11bn; $1.25bn) or more needed to bring a new antibiotic to market..."

[drc007]

Drug-resistant infections: transforming the global response

We want to transform the world's approach towards stemming the rise and spread of drug-resistant infections. Antibiotics are a vital part of modern medicine but their overuse and inappropriate use in humans and animals has caused one of the most urgent global health problems.

https://wellcome.ac.uk/what-we-do/our-work/drug-resistant-infections?utm_source=twitter&utm_medium=o-wellcome